- Home
- VALN vs KALV Comparison
VALN vs KALV Comparison
Compare VALN & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALN
- KALV
- Stock Information
- Founded
- VALN 2012
- KALV N/A
- Country
- VALN France
- KALV United States
- Employees
- VALN N/A
- KALV N/A
- Industry
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- VALN Health Care
- KALV Health Care
- Exchange
- VALN Nasdaq
- KALV Nasdaq
- Market Cap
- VALN 488.9M
- KALV 523.1M
- IPO Year
- VALN 2021
- KALV N/A
- Fundamental
- Price
- VALN $4.66
- KALV $9.49
- Analyst Decision
- VALN Strong Buy
- KALV Strong Buy
- Analyst Count
- VALN 2
- KALV 4
- Target Price
- VALN $18.50
- KALV $29.00
- AVG Volume (30 Days)
- VALN 22.7K
- KALV 338.6K
- Earning Date
- VALN 11-07-2024
- KALV 12-05-2024
- Dividend Yield
- VALN N/A
- KALV N/A
- EPS Growth
- VALN N/A
- KALV N/A
- EPS
- VALN N/A
- KALV N/A
- Revenue
- VALN $176,817,979.00
- KALV N/A
- Revenue This Year
- VALN $24.30
- KALV N/A
- Revenue Next Year
- VALN $16.05
- KALV $179.39
- P/E Ratio
- VALN N/A
- KALV N/A
- Revenue Growth
- VALN N/A
- KALV N/A
- 52 Week Low
- VALN $4.60
- KALV $7.39
- 52 Week High
- VALN $12.85
- KALV $16.88
- Technical
- Relative Strength Index (RSI)
- VALN 26.32
- KALV 33.65
- Support Level
- VALN $4.63
- KALV $10.78
- Resistance Level
- VALN $5.28
- KALV $11.62
- Average True Range (ATR)
- VALN 0.18
- KALV 0.79
- MACD
- VALN -0.09
- KALV -0.20
- Stochastic Oscillator
- VALN 4.05
- KALV 4.27
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.